Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.45 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.42 |
| ▸ | MDM4 | O15151 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TLR2 | O60603 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19709440 | 0.90 | MDM2 (0.46) | CASP3MDM2MDM4TP53TLR2 | |
| SCHEMBL29670299 | 0.89 | CASP3 (0.51) | CASP3MDM4TP53KMT2ATLR2 | |
| SCHEMBL29670423 | 0.87 | CASP3 (0.46) | CASP3MDM2MDM4TP53KMT2A | |
| SCHEMBL29670446 | 0.86 | CASP3 (0.47) | CASP3MDM2MDM4TP53KMT2A | |
| SCHEMBL29670293 | 0.85 | CASP3 (0.44) | CASP3MDM2MDM4TP53KMT2A | |
| SCHEMBL16095689 | 0.83 | KMT2A (0.38) | CASP3MDM2MDM4TP53KMT2A | |
| SCHEMBL18291346 | 0.83 | KMT2A (0.38) | CASP3MDM2MDM4TP53KMT2A | |
| SCHEMBL16095686 | 0.83 | KMT2A (0.38) | CASP3MDM2MDM4TP53KMT2A | |
| SCHEMBL31714105 | 0.83 | KMT2A (0.38) | CASP3MDM2MDM4TP53KMT2A | |
| SCHEMBL29398672 | 0.83 | KMT2A (0.38) | CASP3MDM2MDM4TP53KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12240871-B2 | Method for producing peptide compound | NISSAN CHEMICAL CORPORATION (JP) | 2025-03-04 | — | — | US | disclosed |
| US-20220153777-A1 | METHOD FOR PRODUCING PEPTIDE COMPOUND | NISSAN CHEMICAL CORPORATION (JP) | 2022-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12240871-B2 | Method for producing peptide compound | NGLY1, NPPA, NPEPPS | CASP3 1076/4885MDM2 2420/4885MDM4 2239/4885 |
| US-20220153777-A1 | METHOD FOR PRODUCING PEPTIDE COMPOUND | NGLY1, NPPA, NPEPPS | CASP3 1076/4885MDM2 2420/4885MDM4 2239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.